EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • October 4th, 2011 • Newlink Genetics Corp • Pharmaceutical preparations • Pennsylvania
THIS EXCLUSIVE LICENSE AGREEMENT (the “Agreement”) is made and entered into by and between LANKENAU INSTITUTE FOR MEDICAL RESEARCH (“LIMR”) and NEWLINK GENETICS CORPORATION (“NewLink”) for the licensing of certain intellectual property rights to NewLink, effective on this day of October, 2007 (the “Effective Date”).
EXCLUSIVE LICENSE AGREEMENT between THE REGENTS OF THE UNIVERSITY OF CALIFORNIA and BIOPROTECTION SYSTEMS CORPORATION for “Recombinant Yellow Fever Virus as a Vaccine Vector” [*]Exclusive License Agreement • October 4th, 2011 • Newlink Genetics Corp • Pharmaceutical preparations • California
This license agreement (“Agreement”) is made effective this 29th day of July, 2008 (“Effective Date”), by and between The Regents of the University of California, a California corporation, having its statewide administrative offices at 1111 Franklin Street, 12th Floor, Oakland, California 94607-5200 (“The Regents”), and acting through its Office of Technology Management, University of California San Francisco (“UCSF”), 185 Berry Street, Suite 4603, San Francisco, California 94107, and BioProtection Systems Corporation, a Delaware corporation, having a principal place of business at 2901 South Loop Drive, Suite 3360, Ames, Iowa 50010-8646 (“Licensee”).
ContractStock Subscription Agreement • October 4th, 2011 • Newlink Genetics Corp • Pharmaceutical preparations • Georgia
THIS LICENSE AGREEMENT is made and entered into as of this 13 day of September, 2005, by and between the MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE, INC., a nonprofit Georgia corporation with offices located in the Medical College of Georgia, 1462 Laney Walker Blvd, Room CA-2125, Augusta, Georgia 30912-4810 (hereinafter referred to as “MCGRI”) and NEWLINK GENETICS CORPORATION, a Delaware corporation with corporate headquarters located at 2901 South Loop Drive Suite 3900, Ames, Iowa 50010 (hereinafter referred to as “LICENSEE”).
May 7, 2007 Dr. Charles Link NewLink Genetics Corporation Suite 3900 Ames, IA 50010 USAResearch and Development Agreement • October 4th, 2011 • Newlink Genetics Corp • Pharmaceutical preparations • District of Columbia
Re: Letter of Intent for a Cooperative Research and Development Agreement #02166 NCI Principal Investigators: Drs. Sherry S. Ansher, Lee Jia and Howard Streicher Collaborator Investigators: Drs. Charles Link and Nicholas Vahanian
LICENSE AGREEMENT BETWEEN NEWLINK GENETICS AND DREXEL UNIVERSITY EFFECTIVE AS OF OCTOBER 13th, 2004License Agreement • October 4th, 2011 • Newlink Genetics Corp • Pharmaceutical preparations • Delaware
This License Agreement (this “Agreement”) is made on October, 13th, 2004, by and between Drexel University, a Pennsylvania nonprofit corporation, with offices located at 3201 Arch Street, Suite 100, Philadelphia, Pennsylvania 19104 (“DREXEL”), and NewLink Genetics Corporation, a Delaware for-profit corporation (“LICENSEE”), with its principal offices at Iowa State University Research Park, 2901 South Loop Drive, Suite 3900. This Agreement is effective as of October, 13th, 2004 (the “Effective Date”).
LICENSE AGREEMENT Between: THE UNIVERSITY OF BRITISH COLUMBIA and NEWLINK GENETICS CORPORATIONLicense Agreement • October 4th, 2011 • Newlink Genetics Corp • Pharmaceutical preparations • British Columbia
THE UNIVERSITY OF BRITISH COLUMBIA, a corporation continued under the University Act of British Columbia with its administrative offices at 2075 Wesbrook Mall, Vancouver, British Columbia, V6T 1W5
LICENSE AGREEMENT BETTWEEN LANKENAU INSTITUTE FOR MEDICAL RESEARCH AND NEWLINK GENETICS CORPORATIONLicense Agreement Bettween Lankenau Institute • October 4th, 2011 • Newlink Genetics Corp • Pharmaceutical preparations • Pennsylvania
This License Agreement between Lankenau Institute for Medical Research (“LIMR” or “Institute”) and NewLink Genetics Corporation. (“NewLink” or “Company”) (referred to as “Agreement”) for the licensing of certain intellectual property rights to NewLink is made on this 7th day of July, 2005 (“Effective Date”).
LICENSE AGREEMENT BETWEEN CENTRAL IOWA HEALTH SYSTEM AND NEWLINK GENETICS CORPORATIONLicense Agreement • October 4th, 2011 • Newlink Genetics Corp • Pharmaceutical preparations • Iowa
THIS LICENSE AGREEMENT (the “Agreement”), by and between CENTRAL IOWA HEALTH SYSTEM, a not-for-profit corporation, organized and existing under the laws of the state of Iowa (“CIHS”), and NEWLINK GENETICS CORPORATION, a Delaware corporation, having a principal place of business at 2901 S. Loop Drive, Ames, Iowa, 50010 (“NEWLINK”) is effective as of the 2nd day of August, 2001(the “Effective Date”). CIHS and NEWLINK are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
HER MAJESTY THE QUEEN IN RIGHT OF CANADA, as represented by the Minister of Health, acting through the Public Health Agency of Canada (“Canada”)License Agreement • October 4th, 2011 • Newlink Genetics Corp • Pharmaceutical preparations • Ontario
NOW THEREFORE in consideration of the premises, the terms and conditions hereinafter contained and other good and valuable consideration, the receipt of which is hereby acknowledged by each party, the Parties hereto covenant and agree as follows:
LICENSE AGREEMENT AMENDMENTLicense Agreement • October 4th, 2011 • Newlink Genetics Corp • Pharmaceutical preparations
Inasmuch as NewLink Genetics Corporation of Ames, Iowa, and the Medical College of Georgia Research Institute of Augusta Georgia, have a valid and existing License Agreement related to the use of Indoleamine-2,3-Dioxygenase and its inhibitors in Immuno-regulation [*] dated September 13, 2005;
LICENSE AGREEMENT AMENDMENTLicense Agreement • October 4th, 2011 • Newlink Genetics Corp • Pharmaceutical preparations
Inasmuch as NewLink Genetics Corporation of Ames, Iowa, and the Medical College of Georgia Research Institute of Augusta Georgia, have a valid and existing License Agreement related to the use of Indoleamine-2,3-Dioxygenase and its inhibitors in Immuno-regulation [*] dated September 13, 2005;
LICENSE AGREEMENT AMENDMENTLicense Agreement • October 4th, 2011 • Newlink Genetics Corp • Pharmaceutical preparations
Inasmuch as NewLink Genetics Corporation of Ames, Iowa, and the Medical College of Georgia Research Institute of Augusta Georgia, have a valid and existing License Agreement related to the use of Indoleamine-2,3-Dioxygenase and its inhibitors in Immuno-regulation [*] dated September 13, 2005;
